zonisamide ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2872 68291-97-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • zonisamide
  • exceglan
  • excegram
  • excegran
  • zonegran
an antiseizure drug chemically classified as a sulfonamide and unrelated to other antiseizure agents, blocks sodium channels and reduces voltage-dependent, transient inward currents (T-type Ca2+ currents), consequently stabilizing neuronal membranes and suppressing neuronal hypersynchronization
  • Molecular weight: 212.22
  • Formula: C8H8N2O3S
  • CLOGP: -0.36
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 86.19
  • ALOGS: -2.01
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.20 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.80 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 22 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 40.39 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 99 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
March 27, 2000 FDA EISAI INC
March 10, 2005 EMA
Dec. 4, 2008 PMDA Dainippon Sumitomo Pharma Co., Ltd.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Seizure 750.14 14.60 419 11571 117455 50475679
Multiple-drug resistance 192.45 14.60 58 11932 3256 50589878
Drug reaction with eosinophilia and systemic symptoms 155.58 14.60 92 11898 28332 50564802
Epilepsy 142.66 14.60 79 11911 21488 50571646
Status epilepticus 125.55 14.60 62 11928 13344 50579790
Generalised tonic-clonic seizure 123.01 14.60 77 11913 26233 50566901
Atonic seizures 119.55 14.60 28 11962 584 50592550
Stevens-Johnson syndrome 82.86 14.60 56 11934 21696 50571438
Irritability 73.73 14.60 58 11932 28368 50564766
Focal dyscognitive seizures 70.69 14.60 26 11964 2706 50590428
Aggression 70.19 14.60 50 11940 21066 50572068
Cognitive disorder 68.05 14.60 67 11923 44056 50549078
Product substitution issue 65.32 14.60 41 11949 14016 50579118
Drug eruption 65.20 14.60 50 11940 23556 50569578
Psychotic disorder 62.00 14.60 47 11943 21765 50571369
Ataxia 61.04 14.60 39 11951 13747 50579387
Suicidal behaviour 59.61 14.60 22 11968 2312 50590822
Drug ineffective 58.27 14.60 361 11629 818972 49774162
Somnolence 57.92 14.60 119 11871 154866 50438268
Partial seizures 56.20 14.60 26 11964 4839 50588295
Petit mal epilepsy 55.65 14.60 23 11967 3266 50589868
Drug withdrawal convulsions 54.84 14.60 18 11972 1335 50591799
Choroidal effusion 54.28 14.60 14 11976 440 50592694
Dyskinesia 53.90 14.60 48 11942 27813 50565321
Therapeutic response unexpected 53.61 14.60 38 11952 15877 50577257
Vestibular migraine 53.49 14.60 12 11978 205 50592929
Hyperammonaemic encephalopathy 44.35 14.60 17 11973 1982 50591152
Infantile spasms 42.99 14.60 10 11980 202 50592932
Ovarian granulosa-theca cell tumour 40.38 14.60 7 11983 27 50593107
Depression 38.84 14.60 106 11884 165317 50427817
Drug interaction 38.31 14.60 119 11871 199502 50393632
Tonic convulsion 37.65 14.60 13 11977 1126 50592008
Drug resistance 35.31 14.60 32 11958 18957 50574177
Toxic epidermal necrolysis 34.45 14.60 33 11957 20959 50572175
Diplopia 32.99 14.60 31 11959 19229 50573905
Epileptic psychosis 32.42 14.60 6 11984 36 50593098
Abortion spontaneous 31.59 14.60 44 11946 41728 50551406
Brown tumour 31.50 14.60 6 11984 43 50593091
Oculomucocutaneous syndrome 31.40 14.60 7 11983 116 50593018
Joint swelling 30.62 14.60 10 11980 245276 50347858
Placental infarction 30.27 14.60 8 11982 277 50592857
Diarrhoea 29.96 14.60 59 11931 588417 50004717
Bipolar disorder 29.62 14.60 19 11971 6738 50586396
Dyspnoea 29.54 14.60 53 11937 547555 50045579
Migraine 29.49 14.60 59 11931 75221 50517913
Therapeutic response changed 29.45 14.60 10 11980 823 50592311
Intentional overdose 29.45 14.60 53 11937 62451 50530683
Hallucination, visual 28.99 14.60 27 11963 16555 50576579
Mood altered 28.74 14.60 24 11966 12749 50580385
Suicidal ideation 28.73 14.60 49 11941 55336 50537798
Calculus urinary 28.19 14.60 10 11980 938 50592196
Myoclonic epilepsy 27.91 14.60 10 11980 965 50592169
Therapeutic product effective for unapproved indication 27.60 14.60 6 11984 88 50593046
Rheumatoid arthritis 27.59 14.60 7 11983 202543 50390591
Lichen planus 27.38 14.60 12 11978 1967 50591167
Arthralgia 26.89 14.60 39 11951 438663 50154471
Depressed mood 25.97 14.60 36 11954 33987 50559147
Disturbance in attention 25.32 14.60 34 11956 31152 50561982
Suicide attempt 24.54 14.60 44 11946 51688 50541446
Anticonvulsant drug level increased 24.51 14.60 10 11980 1374 50591760
Encapsulating peritoneal sclerosis 24.38 14.60 7 11983 331 50592803
Hallucination, auditory 23.81 14.60 20 11970 10708 50582426
Systemic lupus erythematosus 23.13 14.60 3 11987 140619 50452515
Endometrial cancer 23.08 14.60 12 11978 2871 50590263
Exposure during pregnancy 23.04 14.60 72 11918 120943 50472191
Therapeutic product ineffective for unapproved indication 22.75 14.60 6 11984 206 50592928
Hepatic function abnormal 22.61 14.60 33 11957 32648 50560486
Arthropathy 22.39 14.60 5 11985 157901 50435233
Swelling 22.05 14.60 10 11980 200862 50392272
Delusion 22.02 14.60 19 11971 10550 50582584
Microcephaly 21.98 14.60 8 11982 808 50592326
Altered state of consciousness 21.10 14.60 26 11964 21884 50571250
Anger 20.87 14.60 19 11971 11314 50581820
Depressed level of consciousness 20.68 14.60 41 11949 51912 50541222
Myoclonus 20.50 14.60 21 11969 14449 50578685
Withdrawal syndrome 20.47 14.60 23 11967 17567 50575567
Hallucination 20.01 14.60 38 11952 46619 50546515
Retinogram abnormal 19.94 14.60 5 11985 140 50592994
Agitation 19.90 14.60 41 11949 53343 50539791
Upper respiratory tract inflammation 19.29 14.60 10 11980 2379 50590755
Coma 19.25 14.60 42 11948 56837 50536297
Anticonvulsant drug level decreased 19.17 14.60 8 11982 1163 50591971
Insomnia 19.06 14.60 87 11903 174778 50418356
Magnetic resonance imaging head abnormal 18.99 14.60 9 11981 1768 50591366
Restless legs syndrome 18.87 14.60 21 11969 15876 50577258
Dysmetria 18.85 14.60 6 11984 403 50592731
Drug level increased 18.77 14.60 23 11967 19245 50573889
Product complaint 18.76 14.60 18 11972 11448 50581686
Aphasia 18.60 14.60 28 11962 28466 50564668
Developmental delay 18.40 14.60 8 11982 1286 50591848
Abnormal behaviour 18.40 14.60 23 11967 19635 50573499
Sinus arrhythmia 17.97 14.60 8 11982 1361 50591773
Infusion related reaction 17.75 14.60 9 11981 169548 50423586
Placental disorder 17.64 14.60 8 11982 1422 50591712
Neuroleptic malignant syndrome 17.33 14.60 17 11973 11113 50582021
Myopia 17.20 14.60 8 11982 1505 50591629
Sudden unexplained death in epilepsy 16.46 14.60 5 11985 288 50592846
Pain 16.45 14.60 76 11914 578827 50014307
Human herpes virus 6 serology positive 16.35 14.60 4 11986 101 50593033
Ureterolithiasis 16.34 14.60 8 11982 1687 50591447
Hypothermia 16.23 14.60 17 11973 11999 50581135
Electrocardiogram PR prolongation 16.02 14.60 6 11984 657 50592477
Nystagmus 15.83 14.60 12 11978 5549 50587585
Encephalocele 15.65 14.60 4 11986 121 50593013
Pneumonia aspiration 15.51 14.60 27 11963 30977 50562157
Illiteracy 15.46 14.60 3 11987 24 50593110
Pregnancy 15.11 14.60 26 11964 29551 50563583
Developmental regression 15.05 14.60 3 11987 28 50593106
Angle closure glaucoma 14.96 14.60 8 11982 2026 50591108
High-pitched crying 14.95 14.60 3 11987 29 50593105
Renal hypoplasia 14.86 14.60 3 11987 30 50593104

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Seizure 496.64 17.30 311 7810 92812 29473594
Status epilepticus 248.37 17.30 98 8023 10696 29555710
Generalised tonic-clonic seizure 119.37 17.30 71 8050 19068 29547338
Multiple-drug resistance 105.98 17.30 40 8081 3860 29562546
Somnolence 103.46 17.30 128 7993 93827 29472579
Drug ineffective 94.43 17.30 264 7857 362906 29203500
Aggression 90.02 17.30 76 8045 35465 29530941
Partial seizures 84.68 17.30 34 8087 3869 29562537
Neonatal pneumonia 63.23 17.30 13 8108 122 29566284
Choroidal effusion 61.60 17.30 13 8108 140 29566266
Neonatal hypotension 61.35 17.30 13 8108 143 29566263
Stevens-Johnson syndrome 60.66 17.30 44 8077 16453 29549953
Postictal psychosis 59.86 17.30 13 8108 162 29566244
Nystagmus 58.67 17.30 27 8094 4282 29562124
Epilepsy 58.49 17.30 45 8076 18387 29548019
Ataxia 57.99 17.30 38 8083 12065 29554341
Focal dyscognitive seizures 53.69 17.30 18 8103 1228 29565178
Drug reaction with eosinophilia and systemic symptoms 53.31 17.30 51 8070 27941 29538465
Irritability 49.24 17.30 44 8077 22108 29544298
Psychotic disorder 48.38 17.30 42 8079 20312 29546094
Dyspnoea 48.24 17.30 15 8106 326717 29239689
Calculus urinary 47.12 17.30 16 8105 1135 29565271
Pneumonia aspiration 46.80 17.30 54 8067 36683 29529723
Vitamin D deficiency 43.80 17.30 24 8097 5505 29560901
Product substitution issue 42.00 17.30 28 8093 9144 29557262
Toxic epidermal necrolysis 40.22 17.30 36 8085 18117 29548289
Hyperammonaemic encephalopathy 38.59 17.30 16 8105 1974 29564432
Nephrolithiasis 36.99 17.30 40 8081 25294 29541112
Respiratory disorder neonatal 36.49 17.30 14 8107 1411 29564995
Salivary hypersecretion 34.84 17.30 23 8098 7386 29559020
Delusion 32.58 17.30 26 8095 11190 29555216
Drug withdrawal convulsions 31.86 17.30 12 8109 1149 29565257
Developmental delay 31.86 17.30 15 8106 2503 29563903
Abnormal behaviour 31.14 17.30 35 8086 23092 29543314
Petit mal epilepsy 30.75 17.30 15 8106 2707 29563699
Sudden unexplained death in epilepsy 29.61 17.30 9 8112 447 29565959
Encephalopathy 28.89 17.30 39 8082 31004 29535402
Myoclonus 28.70 17.30 26 8095 13283 29553123
Drug interaction 28.26 17.30 118 8003 197267 29369139
Dyskinesia 28.11 17.30 31 8090 20030 29546376
Cytotoxic oedema 28.08 17.30 7 8114 164 29566242
Condition aggravated 28.00 17.30 96 8025 146199 29420207
Temporal lobe epilepsy 27.80 17.30 7 8114 171 29566235
Atonic seizures 27.42 17.30 7 8114 181 29566225
Altered state of consciousness 26.60 17.30 30 8091 19859 29546547
Parkinsonism 25.81 17.30 19 8102 7259 29559147
Lymphocyte stimulation test positive 25.80 17.30 9 8112 692 29565714
Anticonvulsant drug level increased 25.80 17.30 11 8110 1455 29564951
Drug eruption 25.43 17.30 27 8094 16714 29549692
Aminoaciduria 24.60 17.30 6 8115 128 29566278
Small for dates baby 24.18 17.30 14 8107 3565 29562841
Tachyarrhythmia 23.82 17.30 13 8108 2956 29563450
Wrong schedule 23.81 17.30 6 8115 147 29566259
Congenital inguinal hernia 23.44 17.30 6 8115 157 29566249
Hallucination 23.23 17.30 43 8078 44669 29521737
Myoclonic epilepsy 22.91 17.30 9 8112 966 29565440
Infantile spasms 22.56 17.30 6 8115 183 29566223
Congenital cutis laxa 22.35 17.30 5 8116 72 29566334
Foetal exposure during pregnancy 22.07 17.30 36 8085 33831 29532575
Death 21.74 17.30 38 8083 342046 29224360
Fanconi syndrome 21.71 17.30 10 8111 1588 29564818
Premature baby 21.32 17.30 25 8096 17255 29549151
Arthralgia 21.28 17.30 6 8115 139611 29426795
Angle closure glaucoma 20.74 17.30 8 8113 817 29565589
Retinogram abnormal 20.27 17.30 5 8116 112 29566294
Product lot number issue 20.25 17.30 4 8117 30 29566376
Language disorder 19.77 17.30 10 8111 1949 29564457
Implant site pruritus 19.52 17.30 3 8118 3 29566403
Hepatic function abnormal 19.45 17.30 37 8084 39222 29527184
Aura 19.36 17.30 6 8115 318 29566088
Hallucination, visual 18.98 17.30 22 8099 14993 29551413
Persecutory delusion 18.93 17.30 10 8111 2131 29564275
Idiopathic generalised epilepsy 18.79 17.30 4 8117 45 29566361
Febrile neutropenia 18.70 17.30 4 8117 112236 29454170
Oculomucocutaneous syndrome 18.33 17.30 5 8116 168 29566238
Assisted delivery 18.31 17.30 3 8118 6 29566400
Implant site rash 18.31 17.30 3 8118 6 29566400
Electroencephalogram abnormal 18.12 17.30 10 8111 2325 29564081
Depressive symptom 18.02 17.30 9 8112 1708 29564698
Macrocephaly 17.79 17.30 6 8115 417 29565989
Haemoglobin decreased 17.77 17.30 4 8117 108371 29458035

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Seizure 687.98 15.14 457 15517 166435 64316323
Status epilepticus 306.32 15.14 135 15839 21528 64461230
Multiple-drug resistance 199.59 15.14 71 15903 6431 64476327
Drug reaction with eosinophilia and systemic symptoms 192.79 15.14 136 15838 54081 64428677
Generalised tonic-clonic seizure 177.58 15.14 115 15859 39742 64443016
Epilepsy 162.42 15.14 102 15872 33429 64449329
Aggression 143.86 15.14 107 15867 46125 64436633
Somnolence 125.28 15.14 199 15775 203446 64279312
Stevens-Johnson syndrome 124.21 15.14 87 15887 34162 64448596
Drug ineffective 119.90 15.14 466 15508 839781 63642977
Choroidal effusion 113.10 15.14 27 15947 585 64482173
Partial seizures 107.95 15.14 47 15927 7260 64475498
Irritability 107.53 15.14 82 15892 36664 64446094
Psychotic disorder 98.63 15.14 76 15898 34502 64448256
Focal dyscognitive seizures 97.46 15.14 35 15939 3255 64479503
Ataxia 91.68 15.14 61 15913 22023 64460735
Atonic seizures 90.78 15.14 23 15951 642 64482116
Hyperammonaemic encephalopathy 79.78 15.14 32 15942 4026 64478732
Petit mal epilepsy 79.69 15.14 34 15940 4998 64477760
Dyskinesia 77.82 15.14 70 15904 39318 64443440
Drug eruption 68.99 15.14 63 15911 36073 64446685
Nystagmus 66.16 15.14 36 15938 9032 64473726
Drug interaction 65.85 15.14 218 15756 361865 64120893
Toxic epidermal necrolysis 63.65 15.14 61 15913 37105 64445653
Calculus urinary 63.57 15.14 22 15952 1835 64480923
Postictal psychosis 62.69 15.14 13 15961 143 64482615
Dyspnoea 62.51 15.14 52 15922 718622 63764136
Cognitive disorder 61.52 15.14 72 15902 55015 64427743
Pneumonia aspiration 57.28 15.14 72 15902 59199 64423559
Delusion 54.45 15.14 41 15933 17973 64464785
Drug withdrawal convulsions 53.26 15.14 20 15954 2108 64480650
Tonic convulsion 51.94 15.14 19 15955 1862 64480896
Suicidal behaviour 50.71 15.14 21 15953 2866 64479892
Drug resistance 47.98 15.14 51 15923 35051 64447707
Altered state of consciousness 43.07 15.14 50 15924 37852 64444906
Hallucination, visual 42.65 15.14 43 15931 27791 64454967
Myoclonus 42.57 15.14 41 15933 25077 64457681
Hepatic function abnormal 42.41 15.14 65 15909 64248 64418510
Lymphocyte stimulation test positive 41.36 15.14 14 15960 1092 64481666
Ovarian granulosa-theca cell tumour 40.72 15.14 7 15967 24 64482734
Myoclonic epilepsy 39.84 15.14 15 15959 1593 64481165
Neonatal pneumonia 39.29 15.14 7 15967 31 64482727
Neonatal hypotension 39.29 15.14 7 15967 31 64482727
Retinogram abnormal 38.52 15.14 10 15964 308 64482450
Vitamin D deficiency 38.45 15.14 28 15946 11664 64471094
Arthralgia 38.35 15.14 32 15942 442228 64040530
Abnormal behaviour 37.61 15.14 44 15930 33578 64449180
Anticonvulsant drug level increased 37.44 15.14 16 15958 2361 64480397
Nephrolithiasis 37.40 15.14 50 15924 43633 64439125
Placental infarction 36.86 15.14 8 15966 111 64482647
Salivary hypersecretion 35.34 15.14 27 15947 12086 64470672
Respiratory disorder neonatal 35.33 15.14 7 15967 60 64482698
Hallucination 35.18 15.14 64 15910 72724 64410034
Infantile spasms 34.77 15.14 9 15965 274 64482484
Oculomucocutaneous syndrome 33.65 15.14 9 15965 312 64482446
Angle closure glaucoma 32.56 15.14 15 15959 2642 64480116
Product substitution issue 31.87 15.14 30 15944 17831 64464927
Sudden unexplained death in epilepsy 31.84 15.14 10 15964 615 64482143
Diplopia 31.57 15.14 36 15938 26729 64456029
Brown tumour 30.88 15.14 6 15968 46 64482712
Febrile neutropenia 30.38 15.14 5 15969 187652 64295106
Upper respiratory tract inflammation 30.35 15.14 16 15958 3766 64478992
Fanconi syndrome 30.28 15.14 14 15960 2487 64480271
Joint swelling 30.23 15.14 8 15966 215374 64267384
Vestibular migraine 29.90 15.14 7 15967 139 64482619
Hallucination, auditory 27.48 15.14 27 15947 16912 64465846
Bronchial hyperreactivity 27.14 15.14 13 15961 2499 64480259
Neuroleptic malignant syndrome 26.78 15.14 32 15942 24964 64457794
Disturbance in attention 26.35 15.14 41 15933 41033 64441725
Therapeutic product effective for unapproved indication 26.29 15.14 6 15968 106 64482652
Therapeutic response unexpected 25.56 15.14 26 15948 16975 64465783
Therapeutic product ineffective for unapproved indication 25.49 15.14 6 15968 122 64482636
Suicidal ideation 25.43 15.14 53 15921 66489 64416269
Breast disorder 25.42 15.14 11 15963 1673 64481085
Parkinsonism 25.37 15.14 24 15950 14349 64468409
Magnetic resonance imaging head abnormal 24.60 15.14 12 15962 2400 64480358
Depression 24.47 15.14 100 15874 183191 64299567
Hyperammonaemia 24.43 15.14 20 15954 9884 64472874
Cytotoxic oedema 24.41 15.14 7 15967 315 64482443
Encephalopathy 23.84 15.14 48 15926 58771 64423987
Swelling 22.38 15.14 6 15968 160212 64322546
Human herpes virus 6 serology positive 22.35 15.14 6 15968 211 64482547
Small for dates baby 22.26 15.14 7 15967 432 64482326
Encephalocele 21.89 15.14 4 15970 21 64482737
Aminoaciduria 21.82 15.14 6 15968 231 64482527
Diarrhoea 21.56 15.14 99 15875 722605 63760153
Mood swings 21.46 15.14 24 15950 17444 64465314
Depressed level of consciousness 21.40 15.14 56 15918 81380 64401378
Anticonvulsant drug level decreased 21.40 15.14 10 15964 1820 64480938
Overdose 21.24 15.14 87 15887 159479 64323279
Placental disorder 21.13 15.14 8 15966 862 64481896
Condition aggravated 21.07 15.14 161 15813 372265 64110493
Illiteracy 21.03 15.14 4 15970 27 64482731
Dysmetria 20.90 15.14 8 15966 888 64481870
Low birth weight baby 20.62 15.14 7 15967 551 64482207
Wrong schedule 20.01 15.14 6 15968 316 64482442
Therapeutic response shortened 19.93 15.14 18 15956 10152 64472606
Infusion related reaction 19.75 15.14 8 15966 164459 64318299
Migraine 19.52 15.14 46 15928 62631 64420127
Developmental regression 19.46 15.14 4 15970 42 64482716
Lichen planus 19.11 15.14 10 15964 2318 64480440
Ureterolithiasis 18.73 15.14 11 15963 3190 64479568
Idiopathic generalised epilepsy 18.60 15.14 4 15970 53 64482705
Agitation 18.54 15.14 56 15918 88311 64394447
Persecutory delusion 18.50 15.14 12 15962 4146 64478612
Personality change 18.41 15.14 16 15958 8577 64474181
Cough 18.41 15.14 29 15945 302119 64180639
Dyscalculia 18.40 15.14 4 15970 56 64482702
Electroencephalogram abnormal 18.34 15.14 13 15961 5190 64477568
Haemoglobin decreased 18.28 15.14 13 15961 195050 64287708
Malaise 18.14 15.14 45 15929 396202 64086556
Mood altered 18.01 15.14 21 15953 15958 64466800
Atrial fibrillation 17.97 15.14 10 15964 171079 64311679
Encapsulating peritoneal sclerosis 17.94 15.14 7 15967 818 64481940
Arthropathy 17.93 15.14 4 15970 120963 64361795
Drug level increased 17.71 15.14 31 15943 34165 64448593
Depressive symptom 17.65 15.14 12 15962 4484 64478274
Osteomalacia 17.51 15.14 8 15966 1383 64481375
Jealous delusion 17.50 15.14 5 15969 222 64482536
Anaemia 17.34 15.14 43 15931 378637 64104121
Human herpesvirus 6 infection 17.27 15.14 12 15962 4642 64478116
Peripheral swelling 17.04 15.14 16 15958 209137 64273621
Torticollis 16.88 15.14 9 15965 2168 64480590
Suicide attempt 16.82 15.14 47 15927 70960 64411798
Brain neoplasm 16.76 15.14 12 15962 4866 64477892
Speech disorder 16.69 15.14 37 15937 48404 64434354
Insomnia 16.31 15.14 94 15880 197742 64285016
Cerebellar atrophy 16.20 15.14 7 15967 1061 64481697
Intentional overdose 16.12 15.14 54 15920 89890 64392868
Aphasia 16.12 15.14 33 15941 40873 64441885
Staring 16.02 15.14 9 15965 2401 64480357
Neutropenia 15.56 15.14 22 15952 239602 64243156
Abdominal pain 15.47 15.14 34 15940 312341 64170417
Gestational diabetes 15.30 15.14 12 15962 5578 64477180

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N03AX15 NERVOUS SYSTEM
ANTIEPILEPTICS
ANTIEPILEPTICS
Other antiepileptics
FDA CS M0020790 Sulfonamides
FDA MoA N0000000235 Carbonic Anhydrase Inhibitors
FDA PE N0000008486 Decreased Central Nervous System Disorganized Electrical Activity
MeSH PA D000927 Anticonvulsants
MeSH PA D002121 Calcium Channel Blockers
MeSH PA D000077264 Calcium-Regulating Hormones and Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D049990 Membrane Transport Modulators
CHEBI has role CHEBI:22586 antioxidants
CHEBI has role CHEBI:35470 central nervous system agents
CHEBI has role CHEBI:35623 anticonvulsants
CHEBI has role CHEBI:50267 protective agents
FDA EPC N0000175753 Anti-epileptic Agent
FDA MoA N0000185503 P-Glycoprotein Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Diffuse Lewy body disease indication 80098002
Partial Epilepsy Treatment Adjunct indication
Suicidal thoughts contraindication 6471006
Agranulocytosis contraindication 17182001 DOID:12987
Mood swings contraindication 18963009
Depressive disorder contraindication 35489007
Metabolic acidosis contraindication 59455009
Diarrhea contraindication 62315008
Psychotic disorder contraindication 69322001
Kidney disease contraindication 90708001 DOID:557
Kidney stone contraindication 95570007
Diminished sweating contraindication 111980002
Disease of liver contraindication 235856003 DOID:409
Aplastic anemia contraindication 306058006 DOID:12449
Severe chronic obstructive pulmonary disease contraindication 313299006
Fever contraindication 386661006
Surgical procedure contraindication 387713003




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.47 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium channel protein type 1 subunit alpha Ion channel BLOCKER WOMBAT-PK CHEMBL
Carbonic anhydrase 2 Enzyme Ki 6.99 WOMBAT-PK
Voltage-dependent T-type calcium channel subunit alpha-1G Ion channel WOMBAT-PK
Carbonic anhydrase 1 Enzyme Ki 7.25 WOMBAT-PK
Carbonic anhydrase 4 Enzyme Ki 5.07 CHEMBL
Amine oxidase [flavin-containing] B Enzyme Ki 5.51 CHEMBL
Carbonic anhydrase 9 Enzyme Ki 8.30 WOMBAT-PK
Carbonic anhydrase 12 Enzyme INHIBITOR Ki 4.96 IUPHAR
Carbonic anhydrase 5A, mitochondrial Enzyme Ki 7.70 CHEMBL
Carbonic anhydrase 5B, mitochondrial Enzyme Ki 5.22 CHEMBL
Carbonic anhydrase 7 Enzyme Ki 6.93 CHEMBL
Carbonic anhydrase 6 Enzyme Ki 7.05 CHEMBL
Carbonic anhydrase 14 Enzyme Ki 5.28 CHEMBL
Carbonic anhydrase 13 Enzyme Ki 6.37 CHEMBL
Carbonic anhydrase V Enzyme Ki 7.69 CHEMBL
Carbonic anhydrase Enzyme Ki 6.66 CHEMBL
Amine oxidase [flavin-containing] B Enzyme Ki 5.54 CHEMBL
Carbonic anhydrase 15 Enzyme Ki 6.20 CHEMBL
Carbonic anhydrase Enzyme Ki 6.97 CHEMBL
Carbonic anhydrase Enzyme Ki 7.46 CHEMBL
Probable transmembrane carbonic anhydrase (Carbonate dehydratase) (Carbonic dehydratase); Transmembrane carbonic anhydrase Enzyme Ki 6.68 CHEMBL
Carbonic anhydrase Enzyme Ki 6.94 CHEMBL
Alpha carbonic anhydrase Enzyme Ki 6.59 CHEMBL
Carbonic anhydrase Enzyme Ki 6.19 CHEMBL
Carbonic anhydrase 2 Enzyme Ki 6.01 CHEMBL
Astrosclerin-3 Enzyme Ki 6.78 CHEMBL
Beta-carbonic anhydrase 1 Enzyme Ki 4.54 CHEMBL
Delta carbonic anhydrase Unclassified Ki 6.39 CHEMBL
Carbonic anhydrase 2 Enzyme Ki 6.06 CHEMBL
Carbonic anhydrase 3 Enzyme Ki 5.07 CHEMBL
Amine oxidase [flavin-containing] Enzyme Ki 4.51 CHEMBL
Carbonic anhydrase Enzyme Ki 6.58 CHEMBL
Carbonic anhydrase, alpha family Unclassified Ki 6.39 CHEMBL
Carbonate dehydratase Enzyme Ki 6.85 CHEMBL
Amine oxidase [flavin-containing] B Enzyme IC50 4.61 CHEMBL

External reference:

IDSource
4021224 VUID
N0000148668 NUI
D00538 KEGG_DRUG
4021224 VANDF
C0078844 UMLSCUI
CHEBI:10127 CHEBI
ZON PDB_CHEM_ID
CHEMBL750 ChEMBL_ID
DB00909 DRUGBANK_ID
D000078305 MESH_DESCRIPTOR_UI
5734 PUBCHEM_CID
5575 INN_ID
7047 IUPHAR_LIGAND_ID
459384H98V UNII
261708 RXNORM
31898 MMSL
73622 MMSL
8781 MMSL
d04527 MMSL
008137 NDDF
125693002 SNOMEDCT_US
398762003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
zonisamide HUMAN PRESCRIPTION DRUG LABEL 1 0615-8266 CAPSULE 100 mg ORAL ANDA 23 sections
ZONISAMIDE HUMAN PRESCRIPTION DRUG LABEL 1 16590-539 CAPSULE 100 mg ORAL ANDA 16 sections
ZONISAMIDE HUMAN PRESCRIPTION DRUG LABEL 1 16590-724 CAPSULE 25 mg ORAL ANDA 13 sections
ZONISAMIDE HUMAN PRESCRIPTION DRUG LABEL 1 21695-155 CAPSULE 100 mg ORAL ANDA 28 sections
ZONISAMIDE HUMAN PRESCRIPTION DRUG LABEL 1 21695-654 CAPSULE 50 mg ORAL ANDA 28 sections
Zonisamide HUMAN PRESCRIPTION DRUG LABEL 1 29300-428 CAPSULE 25 mg ORAL ANDA 12 sections
Zonisamide HUMAN PRESCRIPTION DRUG LABEL 1 29300-429 CAPSULE 50 mg ORAL ANDA 12 sections
Zonisamide HUMAN PRESCRIPTION DRUG LABEL 1 29300-430 CAPSULE 100 mg ORAL ANDA 12 sections
Zonisamide HUMAN PRESCRIPTION DRUG LABEL 1 31722-228 CAPSULE 100 mg ORAL ANDA 25 sections
ZONISAMIDE HUMAN PRESCRIPTION DRUG LABEL 1 33261-843 CAPSULE 100 mg ORAL ANDA 13 sections
ZONISAMIDE HUMAN PRESCRIPTION DRUG LABEL 1 35356-143 CAPSULE 100 mg ORAL ANDA 16 sections
ZONISAMIDE HUMAN PRESCRIPTION DRUG LABEL 1 35356-143 CAPSULE 100 mg ORAL ANDA 16 sections
Zonisamide HUMAN PRESCRIPTION DRUG LABEL 1 43063-932 CAPSULE 25 mg ORAL ANDA 22 sections
Zonisamide HUMAN PRESCRIPTION DRUG LABEL 1 50268-816 CAPSULE 100 mg ORAL ANDA 26 sections
Zonisamide HUMAN PRESCRIPTION DRUG LABEL 1 51407-137 CAPSULE 25 mg ORAL ANDA 22 sections
Zonisamide HUMAN PRESCRIPTION DRUG LABEL 1 51407-137 CAPSULE 25 mg ORAL ANDA 22 sections
Zonisamide HUMAN PRESCRIPTION DRUG LABEL 1 51407-138 CAPSULE 50 mg ORAL ANDA 22 sections
Zonisamide HUMAN PRESCRIPTION DRUG LABEL 1 51407-138 CAPSULE 50 mg ORAL ANDA 22 sections
Zonisamide HUMAN PRESCRIPTION DRUG LABEL 1 51407-139 CAPSULE 100 mg ORAL ANDA 22 sections
Zonisamide HUMAN PRESCRIPTION DRUG LABEL 1 51407-139 CAPSULE 100 mg ORAL ANDA 22 sections
zonisamide HUMAN PRESCRIPTION DRUG LABEL 1 53217-301 CAPSULE 100 mg ORAL ANDA 24 sections
Zonisamide HUMAN PRESCRIPTION DRUG LABEL 1 54868-5789 CAPSULE 100 mg ORAL ANDA 14 sections
Zonisamide HUMAN PRESCRIPTION DRUG LABEL 1 54868-6221 CAPSULE 50 mg ORAL ANDA 14 sections
ZONISAMIDE HUMAN PRESCRIPTION DRUG LABEL 1 55648-945 CAPSULE 25 mg ORAL ANDA 13 sections
ZONISAMIDE HUMAN PRESCRIPTION DRUG LABEL 1 55648-946 CAPSULE 50 mg ORAL ANDA 13 sections
ZONISAMIDE HUMAN PRESCRIPTION DRUG LABEL 1 55648-990 CAPSULE 100 mg ORAL ANDA 13 sections
Zonegran Human Prescription Drug Label 1 59212-680 CAPSULE 100 mg ORAL NDA 26 sections
Zonegran Human Prescription Drug Label 1 59212-681 CAPSULE 25 mg ORAL NDA 26 sections
Zonisamide Human Prescription Drug Label 1 59651-378 CAPSULE 25 mg ORAL ANDA 23 sections
Zonisamide Human Prescription Drug Label 1 59651-379 CAPSULE 50 mg ORAL ANDA 23 sections